8.500USD+2.16%Mkt Cap: 884.04M USDP/E: —Last update: 2026-05-26
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage produ…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap884.04M USD
Enterprise Value600.56M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-129.47M USD
Revenue/Share—
Last Price8.500 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees104
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS68622P1093
Valuation
P/E (Trailing)—
P/E (Forward)-5.46
PEG—
EV/EBITDA-4.04
EV/Revenue—
P/S—
P/B2.17
EPS (TTM)-1.39
EPS (Forward)-1.55
52W Range
5.51532% of range14.93
52W High14.93 USD
52W Low5.515 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-33.68%
ROA-31.66%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-110.97M USD
CapEx (TTM)712.00K USD
FCF Margin—
FCF Yield-7.69%
Net Debt-275.20M USD
Net Debt/EBITDA1.85
Balance Sheet
Debt/Equity0.01
Current Ratio16.33
Quick Ratio15.87
Book Value/Sh3.901 USD
Cash/Share2.724 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)20.36 USD
Target Range15.00 USD – 25.00 USD
# Analysts14
Ownership
Shares Out.103.52M
Float82.53M
Insiders5.85%
Institutions113.71%
Short Interest
Short Ratio9.2d
Short % Float21.49%
Short % Out.21.26%
Shares Short22.01M
Short (prev mo.)19.35M
Technical
SMA 5010.08 (-15.7%)
SMA 20010.85 (-21.7%)
Beta1.10
S&P 52W Chg28.31%
Avg Vol (30d)1.29M
Avg Vol (10d)1.26M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—